aXichem Q2: Our comments - Redeye

Redeye comments on aXichem’s Q2’22 report. We are encouraged to see sales for H1 2022 reaching SEK 1.2m (SEK 0.1m). However, the ramp-up in sales has taken longer than we have expected, and we will shortly return with an update with a case review and financial forecast reconsiderations.

Länk till analysen i sin helhet: https://www.redeye.se/research/853465/axichem-q222-our-comments?utm_source=finwire&utm_medium=RSS